EVMN
Evommune, Inc.
Key Financials
Revenue
$13.0M
↑ 85.7%
Operating Income
$-81071000
↓ 15.8%
Shareholders' Equity
$205.6M
↑ 242.5%
Total Assets
$224.9M
↑ 195.8%
Net Income
$-68870000
↓ 3.1%
EPS (Diluted)
$-11.22
↑ 75.2%
Total Liabilities
$19.4M
↓ 32.0%
Cash & Equivalents
$44.1M
↑ 171.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 424B3 | 6/29/2026 | View on SEC |
| 8-K | 6/29/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 144 | 6/22/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | EVMN |
| Company Name | Evommune, Inc. |
| CIK | 2044725 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 223-7745 |